Mechanistic Roles of Conserved Active-Site Residues in OXA-48 Carbapenem Hydrolysis
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3241-3252
DOI: 10.1021/acsinfecdis.6c00562 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 24.08.2026. Verfasst von Doris M Taylor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas77030, United States. Hauptthemen laut MEDLINE: beta-Lactamases, Carbapenems, Anti-Bacterial Agents. Die Arbeit nennt 51 Literaturangaben. Gefördert von: U.S. Department of Energy, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Carbapenem-hydrolyzing class D β-lactamases are a major source of resistance to last resort β-lactam antibiotics. OXA-48 is a class D β-lactamase that hydrolyzes carbapenems through a catalytic mechanism involving a nucleophilic serine and a carboxylated lysine general base. To define the contributions of conserved active-site residues to catalysis and substrate turnover, alanine substitutions were introduced at key active site positions, followed by steady-state and presteady-state kinetic analysis of mutant enzymes for imipenem and cephalothin hydrolysis. Mutations produced distinct effects, revealing roles in substrate acylation and deacylation reactions. Substitutions at Val120, Trp157, and Leu158 cause the largest decreases in kcat for both imipenem and cephalothin hydrolysis. It is known that deacylation is the rate-limiting step in carbapenem hydrolysis by OXA-48 and presteady-state kinetics analysis shows that the V120A and L158A substitutions further slow the deacylation reaction for imipenem, reducing kcat and kcat/KM values. Our data are also consistent with acylation being rate-limiting for cephalothin hydrolysis, with the V120A and L158A substitutions reducing substrate binding affinity and/or the acylation rate. Structural analysis indicates that the V120A enzyme has open water channel to the noncarboxylated Lys73 while the L158A enzyme is also open to water but has a carboxylated Lys73. Together, these results support a model in which conserved hydrophobic active-site residues optimize the geometric and electrostatic environment required for efficient carbapenem deacylation and turnover. These findings provide mechanistic insight into OXA-48 catalysis that may be exploited to design inhibitors targeting the enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas77030, United States.
- Department of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, California94720, United States.
ORCID-Profile: Dignité Fabrice Ngango, Jiayi Fan, Timothy Palzkill
Förderung
- U.S. Department of Energy
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Taylor, D. M., Ngango, D. F., Fan, J., Park, S., Sankaran, B., Prasad, B. V. V., & Palzkill, T. (2026). Mechanistic Roles of Conserved Active-Site Residues in OXA-48 Carbapenem Hydrolysis. ACS Infectious Diseases, 12(9), 3241-3252. https://doi.org/10.1021/acsinfecdis.6c00562
Vancouver
Taylor DM, Ngango DF, Fan J, Park S, Sankaran B, Prasad BVV, et al. Mechanistic Roles of Conserved Active-Site Residues in OXA-48 Carbapenem Hydrolysis. ACS Infectious Diseases. 2026;12(9):3241-3252. doi:10.1021/acsinfecdis.6c00562
BibTeX
@article{Taylor2026,
author = {Taylor, Doris M and Ngango, Dignité Fabrice and Fan, Jiayi and Park, Suhyeorn and Sankaran, Banumathi and Prasad, B V Venkataram and Palzkill, Timothy},
title = {Mechanistic Roles of Conserved Active-Site Residues in OXA-48 Carbapenem Hydrolysis},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3241--3252},
doi = {10.1021/acsinfecdis.6c00562}
}
EUVIMED